IDSA Recommendations for Nystatin Use in Adult Oral Thrush

Mild Disease (First‑Line Topical Therapy)

The Infectious Diseases Society of America (IDSA) gives a strong recommendation (moderate‑quality evidence) that nystatin may be used as an alternative agent for mild oropharyngeal candidiasis in adults. 1, 2, 3
Nystatin suspension (100,000 U/mL) – 4–6 mL swished and retained in the mouth, four times daily for 7–14 days. 1
Nystatin pastilles (200,000 U each) – 1–2 pastilles allowed to dissolve slowly, four times daily for 7–14 days. 1
The IDSA‑endorsed standard dose for pastilles remains 200,000 U per pastille. 1

Nystatin is not recommended for moderate‑to‑severe oral thrush; the IDSA issues a strong recommendation (high‑quality evidence) for oral fluconazole 100–200 mg daily for 7–14 days as first‑line therapy. 1, 2, 3

If oral thrush does not improve after 7–14 days of nystatin, the IDSA advises escalation to oral fluconazole 100–200 mg daily for 7–14 days as the preferred next step. 1
For fluconazole‑refractory cases, the IDSA recommends either itraconazole solution 200 mg once daily or posaconazole suspension 400 mg twice daily for 3 days followed by 400 mg daily. 1, 2

Dentures – Antifungal therapy alone is insufficient; concurrent denture disinfection is mandatory to prevent treatment failure and rapid relapse (IDSA). 1, 2
HIV‑infected adults – Initiation or optimization of antiretroviral therapy is strongly recommended by the IDSA to reduce recurrent oral candidiasis. 1, 2